Sotera Health (SHC) Resumen de Acciones
Sotera Health Company ofrece soluciones de esterilización, pruebas de laboratorio y servicios de asesoramiento para el sector sanitario en Estados Unidos, Canadá, Europa y a escala internacional. Saber más
| Puntuación del snowflake | |
|---|---|
| Valoración | 4/6 |
| Crecimiento futuro | 4/6 |
| Rendimiento pasado | 5/6 |
| Salud financiera | 3/6 |
| Dividendos | 0/6 |
Recompensas
Análisis de riesgos
SHC Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Competidores de Sotera Health Company
Historial de precios y rendimiento
| Precios históricos de las acciones | |
|---|---|
| Precio actual de la acción | US$19.00 |
| Máximo en las últimas 52 semanas | US$19.85 |
| Mínimo de 52 semanas | US$13.09 |
| Beta | 1.78 |
| Cambio en 1 mes | 9.07% |
| Variación en 3 meses | 20.94% |
| Cambio de 1 año | 16.56% |
| Variación en 3 años | 14.67% |
| Variación en 5 años | -25.29% |
| Variación desde la OPV | -24.30% |
Noticias y actualizaciones recientes
Actualización de narrativa • Aug 07
SHC: Raised Outlook And Margin Assumptions Will Support Steady Future Returns
Analysts have raised their price target on Sotera Health from $16.00 to about $18.64, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E levels. What’s in the News for Sotera Health Sotera Health reported strong second quarter and first half 2026 results, with high single digit growth across its business units.Seeking Alpha • Jul 24
Sotera Health: Why We Plan To Own This For Many Years
Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking AlphaRecent updates
Actualización de narrativa • Aug 07
SHC: Raised Outlook And Margin Assumptions Will Support Steady Future Returns
Analysts have raised their price target on Sotera Health from $16.00 to about $18.64, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E levels. What’s in the News for Sotera Health Sotera Health reported strong second quarter and first half 2026 results, with high single digit growth across its business units.Seeking Alpha • Jul 24
Sotera Health: Why We Plan To Own This For Many Years
Summary Sotera's Sterigenics business boasts 50% EBITDA margins, mission-critical regulated services, and cobalt-60 production that is nearly impossible to replicate. At their November 2024 Investor Day, management outlined a 2025-2027 plan targeting 5%-7% organic revenue growth and 5%-8% adjusted EBITDA growth, with at least 50bps of EBITDA margin expansion annually. Shader comes from Viant Medical, where he served as CEO since 2019, and holds a Stanford MBA. Once a medical device is validated for sterilization at a specific facility, changing that facility requires extensive regulatory work, testing, and approval. If the EPA finalizes the strict 2024 rule, Sotera's capital spend is justified, and competitors without the scale to absorb compliance costs will exit. Read the full article on Seeking Alpha
Actualización de narrativa • Jun 25
SHC: Equity Raise And 2026 Earnings Guidance Will Drive Future Upside
The analyst price target for Sotera Health has been nudged higher from $20.13 to about $20.22, reflecting analysts' updated modeling around fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What’s in the News for Sotera Health Sotera Health filed a follow on equity offering of 31,838,253 shares of common stock, classified as a follow on equity offering event.Actualización de narrativa • Jun 04
SHC: Equity Raise And Higher Guidance Are Expected To Drive Upside
Analysts have maintained their $20.13 price target for Sotera Health, citing only small adjustments in assumptions for discount rate, revenue growth, profit margin and future P/E multiples as the basis for keeping their view steady. What's in the News Sotera Health reported Q1 revenues of $280 million, a 10% year on year increase that came in 3.6% above analyst expectations, alongside growth in adjusted EBITDA and margin expansion, according to recent earnings coverage.Artículo de análisis • May 13
Sotera Health's (NASDAQ:SHC) Performance Is Even Better Than Its Earnings Suggest
Sotera Health Company ( NASDAQ:SHC ) just reported healthy earnings but the stock price didn't move much. Investors are...Actualización de narrativa • May 12
SHC: Equity Raise And Reaffirmed 2026 Guidance Will Support Upside
Analysts have trimmed their price target on Sotera Health slightly from $20.50 to $20.13, citing updated assumptions for long term revenue growth, profit margins, and future P/E multiples. What's in the News Sotera Health plans a CEO transition, with Alton Shader set to become CEO and join the board on May 26, 2026.Actualización de narrativa • Apr 27
SHC: Follow On Equity Raise And 2026 Guidance Will Support Upside
Analysts now see a slightly lower price target for Sotera Health, trimming it from $20.75 to $20.50 as small adjustments to fair value, discount rate, revenue growth, profit margin and forward P/E estimates feed into their updated view. What's in the News Sotera Health completed a follow-on equity offering of 25,000,000 common shares, raising about US$381.75m at a price of US$15.27 per share (Key Developments).Actualización de narrativa • Apr 10
SHC: Equity Raise And 2026 Revenue Guidance Will Support Future Upside Potential
Analysts have maintained their $20.75 price target on Sotera Health, with only slight model adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions underpinning the updated view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 common shares, raising about $381.75 million at a price of $15.27 per share (company filing).Actualización de narrativa • Mar 27
SHC: Equity Raise And 2026 Guidance Will Support Future Upside Potential
Analysts are maintaining a price target of $20.75 for Sotera Health, with only modest tweaks to assumptions such as discount rate, long term revenue growth, profit margin and future P/E multiples, supporting an unchanged valuation view. What's in the News Sotera Health completed a follow on equity offering of 25,000,000 shares of common stock, raising approximately $381.75 million at a price of about $15.27 per share (company filing).Actualización de narrativa • Mar 10
SHC: Organic Investment And Margin Expansion Will Support Future Upside Potential
Analysts have raised their price target on Sotera Health to $20.75 from $20.44, citing updated assumptions for the discount rate, revenue growth, profit margin, and future P/E that reflect refreshed views on the company’s risk profile and earnings power. What's in the News Sotera Health filed a follow on equity offering of 25,000,000 shares of common stock, and later completed the offering for proceeds of US$381.75m at a price of US$15.27 per share, indicating recent access to equity capital markets.Actualización de narrativa • Feb 24
SHC: Organic Investment And Deleveraging Will Support Future Upside Potential
Analysts have kept their Sotera Health price target effectively unchanged at about $20.44, reflecting minimal updates to assumptions around the discount rate, long term revenue growth, profit margins, and future P/E expectations. What's in the News Sotera Health signaled that its primary use of capital remains focused on organic growth, with management highlighting continued investment to strengthen existing businesses.Actualización de narrativa • Feb 10
SHC: Organic Capital Deployment Will Support Deleveraging And Undervalued Upside
Analysts have maintained their price target for Sotera Health at approximately US$20.44, making only minor adjustments to inputs such as the discount rate, revenue growth, profit margin, and future P/E used in their valuation models. What's in the News Sotera Health signaled it will continue to focus its capital on organic growth initiatives, with CEO Michael Petras highlighting this as the primary use of funds during the JPMorgan Healthcare Conference (Key Developments).Actualización de narrativa • Jan 26
SHC: Equity Offering And Capital Allocation Priorities Will Guide Balanced Outlook
Analysts have modestly adjusted their price expectations for Sotera Health, with the updated target now at approximately US$20.44. This reflects small tweaks to assumptions such as the discount rate, long-term revenue growth, profit margin and future P/E.
Nueva narrativa • Jan 24
Bullish View Expects Sterilization Demand And Cobalt 60 Stability To Support Long-Term Upside
Catalysts About Sotera Health Sotera Health provides sterilization services and lab testing that support global health care and medical products. What are the underlying business or industry changes driving this perspective?Actualización de narrativa • Jan 12
SHC: Follow-On Equity Offering And Lock-Up Terms Will Shape Balanced Outlook
Analysts have lifted their price target for Sotera Health to US$20.44 from US$18.93, citing updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What's in the News Sotera Health completed a follow on equity offering of 30,000,000 common shares, raising about US$471 million at a price of US$15.70 per share with a US$0.049 discount per share (Key Developments).Artículo de análisis • Jan 09
Is Sotera Health Company (NASDAQ:SHC) Potentially Undervalued?
Sotera Health Company ( NASDAQ:SHC ), is not the largest company out there, but it led the NASDAQGS gainers with a...Actualización de narrativa • Dec 15
SHC: Follow-On Equity Offering Will Drive Bullish Share Performance Next Year
Narrative Update Analysts have modestly raised their price target on Sotera Health, citing fine tuned assumptions around discount rates, revenue growth, margins, and future earnings multiples as justification for a slightly higher implied fair value near $18.93 per share. What's in the News Sotera Health has completed a follow-on equity offering of approximately $471 million, issuing 30 million shares of common stock at about $15.70 per share (Key Developments) The company has filed a separate follow-on equity offering totaling roughly $480.3 million for 30 million shares of common stock, with an indicated price of about $16.01 per share (Key Developments) Executive officers, directors and selling stockholders have agreed to a lock-up on 284,093,929 common shares, restricting most sales and hedging activity from November 6, 2025 to December 7, 2025 (Key Developments) Certain restricted stock units held by insiders are also subject to the same 31-day lock-up period ending December 7, 2025 (Key Developments) Options held by executives, directors and selling stockholders will likewise be restricted during the November 6 to December 7, 2025 lock-up window (Key Developments) Valuation Changes Fair Value: Unchanged at an implied price of approximately $18.93 per share.Actualización de narrativa • Nov 30
SHC: Follow-On Offering And Lock-Up Expiration Will Shape Shares Next Year
Analysts have maintained their price target for Sotera Health at $18.93, citing consistent expectations for growth and profitability metrics along with minor adjustments to underlying discount rates and projected price-to-earnings ratios. What's in the News Sotera Health Company has completed a Follow-on Equity Offering valued at $471 million, issuing 30 million shares of common stock at $15.70 each (Key Developments).Actualización de narrativa • Nov 16
SHC: Improved Profit Margins Will Drive Future Share Price Upside
Analysts have raised their price target for Sotera Health from $17.00 to $18.93 per share. They cite an improved profit margin outlook despite slightly lower revenue growth projections.Artículo de análisis • Nov 11
Sotera Health's (NASDAQ:SHC) Conservative Accounting Might Explain Soft Earnings
The most recent earnings report from Sotera Health Company ( NASDAQ:SHC ) was disappointing for shareholders. However...Artículo de análisis • Nov 07
Results: Sotera Health Company Beat Earnings Expectations And Analysts Now Have New Forecasts
Sotera Health Company ( NASDAQ:SHC ) investors will be delighted, with the company turning in some strong numbers with...Actualización de narrativa • Nov 01
SHC: Recent Equity Offerings And Lock-Up Expiry Will Shape Market Outlook
Narrative Update on Sotera Health Analysts have maintained their price target for Sotera Health at $17.00 per share. They cite unchanged growth expectations and financial metrics that support the previous valuation.Actualización de narrativa • Oct 17
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Narrative Update: Sotera Health Analyst Price Target Adjustment Analysts have raised their price target for Sotera Health from $16.33 to $17.00 per share. This adjustment reflects a more optimistic outlook based on modest improvements in projected fair value and valuation metrics.Actualización de narrativa • Oct 03
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Analysts have modestly raised their price target for Sotera Health from $16.00 to approximately $16.33. This reflects incremental updates in growth and valuation assumptions.Actualización de narrativa • Aug 10
Expanding Sterilization Capacity And EPA Compliance Will Unlock New Markets
Sotera Health's consensus price target has increased to $15.75 as analysts reacted positively to a significant rise in net profit margin and a substantial decline in forward P/E, indicating improved profitability and valuation. What's in the News Sotera Health raised full-year 2025 earnings guidance, increasing expected net revenue growth to 4.5%–6.0% from 4.0%–6.0% on a constant currency basis.Rentabilidad de los accionistas
| SHC | US Life Sciences | Mercado US | |
|---|---|---|---|
| 7D | 0.6% | 2.6% | -0.8% |
| 1Y | 16.6% | 23.0% | 20.5% |
Rentabilidad vs. Industria: SHC igualó a la industria US Life Sciences, que obtuvo un rendimiento del 23% el año pasado.
Rentabilidad vs. Mercado: SHC obtuvo unos resultados inferiores a los del mercado US, que fueron del 20.5% el año pasado.
Volatilidad de los precios
| SHC volatility | |
|---|---|
| SHC Average Weekly Movement | 4.3% |
| Life Sciences Industry Average Movement | 8.0% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.1% |
Precio estable de las acciones: SHC no ha tenido una volatilidad de precios significativa en los últimos 3 meses en comparación con el mercado US.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SHC (4%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2015 | 3,000 | Alton Shader | soterahealth.com |
Sotera Health Company ofrece soluciones de esterilización, pruebas de laboratorio y servicios de asesoramiento para el sector sanitario en Estados Unidos, Canadá, Europa y a escala internacional. La empresa opera a través de tres segmentos: Sterigenics, Nordion y Nelson Labs. El segmento Sterigenics ofrece servicios externalizados de esterilización e irradiación de terminales mediante tecnologías de irradiación gamma, procesamiento de óxido de etileno e irradiación por haz de electrones para los mercados de dispositivos médicos, farmacéuticos, seguridad alimentaria y aplicaciones avanzadas.
Resumen de fundamentos de Sotera Health Company
| Estadísticas fundamentales de SHC | |
|---|---|
| Capitalización bursátil | US$5.28b |
| Beneficios(TTM) | US$163.48m |
| Ingresos (TTM) | US$1.22b |
33.2x
Ratio precio-beneficio (PE)4.5x
Ratio precio-ventas (PS)¿Está SHC sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SHC | |
|---|---|
| Ingresos | US$1.22b |
| Coste de los ingresos | US$547.66m |
| Beneficio bruto | US$668.51m |
| Otros gastos | US$505.04m |
| Beneficios | US$163.48m |
Últimos beneficios comunicados
Jun 30, 2026
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.57 |
| Margen bruto | 54.97% |
| Margen de beneficio neto | 13.44% |
| Ratio deuda/patrimonio | 321.4% |
¿Cómo se ha desempeñado SHC a largo plazo?
Ver rendimiento histórico y comparativaAnálisis de la empresa y estado de los datos financieros
| Datos | Última actualización (huso horario UTC) |
|---|---|
| Análisis de la empresa | 2026/08/19 09:01 |
| Precio de las acciones al final del día | 2026/08/19 00:00 |
| Beneficios | 2026/06/30 |
| Ingresos anuales | 2025/12/31 |
Fuentes de datos
Los datos utilizados en nuestro análisis de empresas proceden de S&P Global Market Intelligence LLC. Los siguientes datos se utilizan en nuestro modelo de análisis para generar este informe. Los datos están normalizados, lo que puede introducir un retraso desde que la fuente está disponible.
| Paquete | Datos | Marco temporal | Ejemplo Fuente EE.UU. * |
|---|---|---|---|
| Finanzas de la empresa | 10 años |
| |
| Estimaciones del consenso de analistas | +3 años |
|
|
| Precios de mercado | 30 años |
| |
| Propiedad | 10 años |
| |
| Gestión | 10 años |
| |
| Principales avances | 10 años |
|
* Ejemplo para valores de EE.UU., para no EE.UU. se utilizan formularios y fuentes normativas equivalentes.
A menos que se especifique lo contrario, todos los datos financieros se basan en un periodo anual, pero se actualizan trimestralmente. Esto se conoce como datos de los últimos doce meses (TTM) o de los últimos doce meses (LTM). Más información.
Modelo de análisis y copo de nieve
Los detalles del modelo de análisis utilizado para generar este informe están disponibles en nuestra página de Github, también tenemos guías sobre cómo utilizar nuestros informes y tutoriales en Youtube.
Conozca al equipo de talla mundial que diseñó y construyó el modelo de análisis Simply Wall St.
Métricas industriales y sectoriales
Simply Wall St calcula cada 6 horas nuestras métricas sectoriales y de sección. Los detalles de nuestro proceso están disponibles en Github.
Fuentes analistas
Sotera Health Company está cubierta por 14 analistas. 9 de esos analistas presentaron las estimaciones de ingresos o ganancias utilizadas como datos para nuestro informe. Las estimaciones de los analistas se actualizan a lo largo del día.
| Analista | Institución |
|---|---|
| Michael Polark | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |